Corine Gaillez

639 total citations
56 papers, 421 citations indexed

About

Corine Gaillez is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Corine Gaillez has authored 56 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Rheumatology, 25 papers in Immunology and 24 papers in Hematology. Recurrent topics in Corine Gaillez's work include Rheumatoid Arthritis Research and Therapies (33 papers), Spondyloarthritis Studies and Treatments (32 papers) and Autoimmune and Inflammatory Disorders Research (24 papers). Corine Gaillez is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (33 papers), Spondyloarthritis Studies and Treatments (32 papers) and Autoimmune and Inflammatory Disorders Research (24 papers). Corine Gaillez collaborates with scholars based in Switzerland, United States and United Kingdom. Corine Gaillez's co-authors include Manuela Le Bars, Maria Antonietta D’Agostino, Esperanza Naredo, Maarten Boers, Laura C. Coates, Richard J. Wakefield, Annamaria Iagnocco, Philip J. Mease, Olivier Vittecoq and Georgios Filippou and has published in prestigious journals such as Annals of the Rheumatic Diseases, Critical Care and Lara D. Veeken.

In The Last Decade

Corine Gaillez

52 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Corine Gaillez Switzerland	11	358	192	188	33	31	56	421
J.G. Ovalles-Bonilla Spain	10	282 0.8×	103 0.5×	59 0.3×	44 1.3×	60 1.9×	29	349
Daniel Glinatsi Denmark	11	360 1.0×	96 0.5×	82 0.4×	32 1.0×	67 2.2×	21	407
M. Luc France	5	294 0.8×	92 0.5×	75 0.4×	11 0.3×	110 3.5×	9	423
Lina Martínez‐Estupiñán Spain	9	171 0.5×	68 0.4×	61 0.3×	22 0.7×	54 1.7×	18	265
Robin M. ten Brinck Netherlands	13	378 1.1×	110 0.6×	71 0.4×	35 1.1×	38 1.2×	19	460
Simon Krabbe Denmark	14	401 1.1×	157 0.8×	138 0.7×	8 0.2×	77 2.5×	46	483
I. Hansen Denmark	7	296 0.8×	109 0.6×	41 0.2×	18 0.5×	44 1.4×	11	345
Petra Hánová Czechia	11	229 0.6×	91 0.5×	127 0.7×	10 0.3×	70 2.3×	21	373
Satyapal Rangaraj United Kingdom	7	166 0.5×	52 0.3×	93 0.5×	9 0.3×	12 0.4×	17	265
Raúl Castellanos‐Moreira Spain	9	158 0.4×	46 0.2×	43 0.2×	18 0.5×	41 1.3×	24	261

Countries citing papers authored by Corine Gaillez

Since Specialization

Citations

This map shows the geographic impact of Corine Gaillez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corine Gaillez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corine Gaillez more than expected).

Fields of papers citing papers by Corine Gaillez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corine Gaillez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corine Gaillez. The network helps show where Corine Gaillez may publish in the future.

Co-authorship network of co-authors of Corine Gaillez

This figure shows the co-authorship network connecting the top 25 collaborators of Corine Gaillez. A scholar is included among the top collaborators of Corine Gaillez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corine Gaillez. Corine Gaillez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Felten, Renaud, et al.. (2023). Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies. RMD Open. 9(4). e003428–e003428. 4 indexed citations

Coates, Laura C., Philip J. Mease, Dafna D. Gladman, et al.. (2023). Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD Open. 9(2). e002939–e002939. 2 indexed citations

Conaghan, Philip G., Maria Antonietta D’Agostino, Maarten Boers, et al.. (2023). E087 Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE trial. Lara D. Veeken. 62(Supplement_2).

D’Agostino, Maria Antonietta, Philippe Carron, Corine Gaillez, et al.. (2023). Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension. Seminars in Arthritis and Rheumatism. 63. 152259–152259. 10 indexed citations

Kaeley, Gurjit S., Georg Schett, Philip G. Conaghan, et al.. (2023). Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. Lara D. Veeken. 63(1). 41–49. 2 indexed citations

D’Agostino, Maria Antonietta, Georg Schett, Ladislav Šenolt, et al.. (2021). Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Lara D. Veeken. 61(5). 1867–1876. 19 indexed citations

Orbai, Ana‐Maria, et al.. (2021). POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5. Annals of the Rheumatic Diseases. 80. 802–803. 1 indexed citations

Coates, Laura C., Peter Nash, Tore K Kvien, et al.. (2020). Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Seminars in Arthritis and Rheumatism. 50(4). 709–718. 22 indexed citations

Baraliakos, Xenofon, Filip Van den Bosch, Pedro Machado, et al.. (2020). Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. Rheumatology and Therapy. 8(1). 273–288. 12 indexed citations

10.

Coates, Laura C., Johan K. Wallman, Dennis McGonagle, et al.. (2019). Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Research & Therapy. 21(1). 266–266. 13 indexed citations

11.

Coates, Laura C., Dafna D. Gladman, Peter Nash, et al.. (2018). Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Research & Therapy. 20(1). 272–272. 27 indexed citations

12.

Coates, Laura C., Philip J. Mease, Laure Gossec, et al.. (2018). Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study. Arthritis Care & Research. 70(10). 1529–1535. 37 indexed citations

13.

Coates, Laura C., Tore K Kvien, Peter Nash, et al.. (2017). AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). Annals of the Rheumatic Diseases. 76. 1326–1326. 2 indexed citations

14.

Coates, Laura C., Peter Nash, Tore K Kvien, et al.. (2017). Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study. Queensland's institutional digital repository (The University of Queensland). 69. 21–22. 1 indexed citations

15.

McInnes, Iain B., T.K. Kvien, Luminita Pricop, et al.. (2017). AB0766 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis (DAPSA): 2 year results from the future 2 study. Annals of the Rheumatic Diseases. 76. 1323–1324. 1 indexed citations

16.

D’Agostino, Maria Antonietta, Richard J. Wakefield, Olivier Vittecoq, et al.. (2016). Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Annals of the Rheumatic Diseases. 75(10). 1763–1769. 66 indexed citations

17.

D’Agostino, Maria Antonietta, Maarten Boers, Richard J. Wakefield, et al.. (2016). Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open. 2(1). e000237–e000237. 53 indexed citations

18.

Huizinga, T., P. Emery, René Westhovens, et al.. (2011). Rate of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Seroconversion in Patients with Undifferentiated Arthritis or Early Rheumatoid Arthritis Treated with Abatacept.. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations

19.

Gaillez, Corine, et al.. (2007). L’atomoxétine (Strattera®), une alternative thérapeutique dans le trouble déficit de l’attention/hyperactivité de l’enfant (TDAH). L Encéphale. 33(4). 621–628. 1 indexed citations

20.

Dhainaut, J. F., et al.. (2003). Mécanismes impliqués dans l'activation de la voie de la protéine C au cours du sepsis.. Annales Françaises d Anesthésie et de Réanimation. 22. 3–11. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact